MDL 29913

• Description:

  MDL 29913, a cyclic pseudopeptide, is a competitive NK2 tachykinin receptor selective antagonist, with a pA2 of 8.66[1].

• UNSPSC:

  12352209

• Target:

  Neurokinin Receptor

• Type:

  Peptides

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/mdl-29913.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N[C@H](C(NCC(NC(CN([C@H](C(N[C@H](C(N1)=O)CCC(N)=O)=O)CC(C)C)C)CC(C)C)=O)=O)CC2=CC=CC=C2)[C@@H]1CC3=CNC4=CC=CC=C34

• Molecular Formula:

  C40H56N8O6

• Molecular Weight:

  744.92

• References & Citations:

  [1]C A Maggi, et al. MEN 10,573 and MEN 10,612, novel cyclic pseudopeptides which are potent tachykinin NK-2 receptor antagonists. Regul Pept. 1993 Sep 3;47 (2) :151-8.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Peptides

• Clinical Information:

  No Development Reported

• CAS Number:

  [135721-56-1]